This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2007 Nov;30(6):843-4.

doi: 10.1007/s10545-007-0783-8.

No justification for very high-dose enzyme therapy for patients with type III Gaucher disease

Ari Zimran, Deborah Elstein

PMID: 18008181
DOI: 10.1007/s10545-007-0783-8

Editorial

No justification for very high-dose enzyme therapy for patients with type III Gaucher disease

Ari Zimran et al. J Inherit Metab Dis. 2007 Nov.

. 2007 Nov;30(6):843-4.

doi: 10.1007/s10545-007-0783-8.

Authors

Ari Zimran, Deborah Elstein

PMID: 18008181
DOI: 10.1007/s10545-007-0783-8

No abstract available

PubMed Disclaimer

Similar articles

Enzyme replacement in Gaucher disease.
Beutler E. Beutler E. PLoS Med. 2004 Nov;1(2):e21. doi: 10.1371/journal.pmed.0010021. Epub 2004 Nov 30. PLoS Med. 2004. PMID: 15578103 Free PMC article. Review.
Therapy of adult Gaucher disease.
Schmitz J, Poll LW, vom Dahl S. Schmitz J, et al. Haematologica. 2007 Feb;92(2):148-52. doi: 10.3324/haematol.11193. Haematologica. 2007. PMID: 17296562 Review. No abstract available.
Enzyme replacement therapy in type III Gaucher disease.
Tylki-Szymańska A, Czartoryska B. Tylki-Szymańska A, et al. J Inherit Metab Dis. 1999 Apr;22(2):203-4. doi: 10.1023/a:1005495229655. J Inherit Metab Dis. 1999. PMID: 10234625 No abstract available.
[Enzyme therapy of Gaucher's disease].
Beck M. Beck M. Dtsch Med Wochenschr. 1993 Jun 25;118(25):964-5. Dtsch Med Wochenschr. 1993. PMID: 8519225 German. No abstract available.
Treatment regimens in Gaucher's disease.
Beutler E. Beutler E. Lancet. 1995 Aug 26;346(8974):581-2. doi: 10.1016/s0140-6736(95)91422-6. Lancet. 1995. PMID: 7658807 No abstract available.

See all similar articles

Cited by

CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.
Marshall J, Sun Y, Bangari DS, Budman E, Park H, Nietupski JB, Allaire A, Cromwell MA, Wang B, Grabowski GA, Leonard JP, Cheng SH. Marshall J, et al. Mol Ther. 2016 Jun;24(6):1019-1029. doi: 10.1038/mt.2016.53. Epub 2016 Mar 7. Mol Ther. 2016. PMID: 26948439 Free PMC article.
Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease.
Cabrera-Salazar MA, Deriso M, Bercury SD, Li L, Lydon JT, Weber W, Pande N, Cromwell MA, Copeland D, Leonard J, Cheng SH, Scheule RK. Cabrera-Salazar MA, et al. PLoS One. 2012;7(8):e43310. doi: 10.1371/journal.pone.0043310. Epub 2012 Aug 17. PLoS One. 2012. PMID: 22912851 Free PMC article.
Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III.
Cox-Brinkman J, van Breemen MJ, van Maldegem BT, Bour L, Donker WE, Hollak CE, Wijburg FA, Aerts JM. Cox-Brinkman J, et al. J Inherit Metab Dis. 2008 Dec;31(6):745-52. doi: 10.1007/s10545-008-0873-2. Epub 2008 Oct 15. J Inherit Metab Dis. 2008. PMID: 18850301
Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
Ashe KM, Bangari D, Li L, Cabrera-Salazar MA, Bercury SD, Nietupski JB, Cooper CG, Aerts JM, Lee ER, Copeland DP, Cheng SH, Scheule RK, Marshall J. Ashe KM, et al. PLoS One. 2011;6(6):e21758. doi: 10.1371/journal.pone.0021758. Epub 2011 Jun 29. PLoS One. 2011. PMID: 21738789 Free PMC article.

References

1. Genet Med. 2005 Feb;7(2):124-30 - PubMed
1. Blood. 2006 Aug 1;108(3):802-3 - PubMed
1. Am J Med Genet. 1997 Jul 11;71(1):16-21 - PubMed
1. Reprod Biomed Online. 2007 Jul;15(1):83-8 - PubMed
1. J Inherit Metab Dis. 2007 Nov;30(6):935-42 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- Genetic Alliance
- MedlinePlus Health Information